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Targeted transcriptional regulation is a powerful tool to study genetic
mediators of cellular behavior. Here, we show that catalytically dead
Cas9 (dCas9) targeted to genomic regions upstream or downstream
of the transcription start site allows for specific and sustainable gene-
expression level alterations in tumor cells in vitro and in syngeneic
immune-competent mouse models. We used this approach for a high-
coverage pooled gene-activation screen in vivo and discovered
previously unidentified modulators of tumor growth and thera-
peutic response. Moreover, by using dCas9 linked to an activation
domain, we can either enhance or suppress target gene expression
simply by changing the genetic location of dCas9 binding relative
to the transcription start site. We demonstrate that these directed
changes in gene-transcription levels occur with minimal off-target
effects. Our findings highlight the use of dCas9-mediated transcrip-
tional regulation as a versatile tool to reproducibly interrogate tumor
phenotypes in vivo.
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Because of the dramatic decline in sequencing costs and theincrease in sequencing efficiency over the last decade (1), the
amount of descriptive knowledge about the cancer genome and
transcriptome has increased exponentially. However, the acqui-
sition of this information has greatly outpaced our capability to
functionally study the biological roles of putative cancer genes (2,
3). Determining the relative contribution of an individual gene
alteration in the context of the many changes found in a given
tumor cell is challenging, as is discriminating cancer-driving mu-
tations from silent ones (4).
The application of nucleases targeted to specific regions of the
genome-like zinc finger nucleases (ZFNs) (5, 6), transcription
activator-like effector nucleases (7), and clustered regularly
interspaced short palindromic repeats (CRISPR) (8, 9) have made
it possible to study the functional relevance of specific genomic
mutations. Most notably, the CRISPR-associated protein 9 (Cas9)
protein can be targeted to genomic regions of interest by easily
programmable short guide RNA (sgRNA) molecules. This ap-
proach has been used to elegantly study mutational phenotypes (10)
and to screen for novel mediators of disease (11–15). However,
most genome editing applications are focused on loss-of-function
phenotypes caused by genomic frameshift mutations, making it hard
to study scenarios in which tumor progression and relapse are
driven by gene activation. This is particularly true for mechanisms
leading to resistance to cancer treatment, where a gene transcript level
may increase by gene amplification (16–20) or mere up-regulation
(21, 22), which can lead to potent resistance phenotypes, ulti-
mately resulting in treatment failure and patient death. In contrast
to transcriptional inactivation, large-scale gene overexpression
studies are technically challenging, costly, and do not allow for a
rapid and flexible pooled library construction (23), underlining the
necessity to develop novel tools amenable for rapid modeling of
gene activation phenotypes.
Catalytically inactive, or dead, Cas9 (dCas9), with its potential to
either activate or inactivate the transcription of specific genes,
has recently emerged as an alternative to genome editing, RNA
interference, and cDNA overexpression. sgRNA molecules are used
to specifically target dCas9, with or without linked effector molecule
domains, to genomic regions of interest. Depending on the targeted
genomic region and on the effector molecule domain, dCas9 can
then either cause transcriptional repression or activation. Whereas
the transcriptional perturbation mediated by dCas9 has efficiently
been used to study in vitro phenotypes in tissue culture cells (24–31),
evidence for long-term sustained in vivo activity and for the feasi-
bility of in vivo gene repression/activation screens is still lacking. One
of the biggest challenges for achieving this goal is that dCas9 has to
be constantly expressed to mediate its inhibitory or activating effects
on transcription. This necessity stands in sharp contrast to applica-
tions of catalytically active Cas9, where, theoretically, a short duration
of Cas9 expression may be enough to create irreversible mutations.
Here, we describe the development and application of a dCas9-
based system capable of long-lasting transcriptional repression and
activation in vitro and in vivo in multiple immune-competent
mouse models of cancer. Additionally, to our knowledge, we
present the first in vivo multiplexed gene activation screen for
mediators of bone marrow treatment relapse in a syngeneic mouse
model for acute lymphoblastic leukemia (ALL). We demonstrate
that this technology is fully amenable to model the functional
consequences of transcriptional changes found in human cancers.
Significance
Tumor development is accompanied by widespread genomic and
transcriptional changes. The mere acquisition of this information
has greatly outpaced our capability to functionally study the bi-
ological roles of altered genes. This dilemma highlights the ne-
cessity to develop technologies that facilitate a rapid functional
prioritization among lists of altered genes. Here, we use cata-
lytically dead Cas9 to specifically activate or inactivate the tran-
scription of genes in mouse models of cancer. This approach
allows us to study the impact of gene-level changes in vivo and
to systematically screen for novel genetic mediators of treatment
relapse. We expect that this approach can be used to systemati-
cally dissect the biological role of cancer-related genes, a process
critical to identifying new cancer drug targets.
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We show that the transcriptional changes are highly specific and
that both gene-induction and gene-inactivation phenotypes can
be achieved by specific genomic targeting of the same dCas9
construct.
Results
Inhibition of Trp53 Transcription by dCas9 Leads to a Potent
Inactivation of TRP53 Function and Resistance to DNA Damage.
CRISPR interference (CRISPRi) can repress transcription ei-
ther by directly interfering with transcriptional initiation (if tar-
geted to the promoter) or by blocking RNA elongation (if targeted
to the first exon of a particular gene) (25, 32). To explore whether
this genetic inactivation is potent enough to model genetic
changes that occur during cancer progression and the evolution of
therapeutic resistance, we coinfected murine Eμ-Myc p19Arf−/−
lymphoma cells (33) with a retroviral vector-expressing dCas9 and
a lentiviral vector expressing specific sgRNAs (Fig. 1 A and B and
SI Appendix, Figs. S1 and S2). We screened multiple sgRNAs
targeting the genomic area around the transcription start site
(TSS) of Trp53 (Fig. 1C), with the goal of using dCas9 as a
“roadblock” that blocks transcriptional elongation (Fig. 1D).
TRP53 is mutated in more than half of all sporadic cancers, and its
activation upon cellular stress can elicit a broad set of cellular
responses including cell cycle arrest, cellular senescence, and ap-
optosis (34–36). Inactivation of TRP53 accelerates oncogene-
mediated tumorigenesis (37) and renders cells less sensitive to
apoptosis (38). Thus, we first investigated which sgRNAs were
best at mediating resistance to DNA damage. To do this, we
partially infected Eμ-Myc p19Arf−/− cells with both dCas9 and
single sgRNAs targeting various places along the Trp53 gene body.
Most sgRNAs were targeted to exon 1, but several others were
targeted both upstream and downstream as negative controls.
These mixed populations of sgRNA-dCas9 expressing and non-
expressing cells were then treated with the DNA damage agent
cisplatin, and the relative composition of sgRNA-dCas9 expressing
to nonexpressing cells was assayed via flow cytometry (Fig. 1E).
We found that all sgRNAs targeting dCas9 to exon 1 of Trp53
promoted cellular resistance to DNA damage (Fig. 1F). In con-
cordance with this result, after cisplatin treatment, TRP53 mRNA
and protein up-regulation was also diminished in the presence of
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Fig. 1. dCas9 targeted to the TSS of Trp53 leads to a potent and sustainable loss of TRP53 function. (A) A vector diagram of MSCV-dCas9-GFP. (B) A vector
diagram of U6-sgRNA-tdTomato. (C) An overview of sgRNA target sites at the murine Trp53 locus. dNC, distal negative control, based on their distant location
from the TSS. pNC, proximal negative control, based on their relatively close location to the TSS. Green represents sgRNAs predicted to knockdown based on
their location in the first exon, just downstream of the TSS. (D) Schematic overview of dCas9-mediated interruption of transcriptional elongation by RNA
polymerase (RNAP). (E) A schematic overview of in vitro competition assays. (F) Normalized fold-enrichment of individual sgRNAs targeting different regions
of the Trp53 locus after cisplatin treatment compared with RNAi (shRNA TRP53). No enrichment would lead to a normalized fold enrichment score of zero.
**P < 0.01 between the two indicated conditions via Student’s t test. Data are represented as mean ± SEM. (G) A Western blot showing a time course of TRP53
and CDKN1A accumulation in Eμ-Myc p19Arf−/− lymphoma after cisplatin (Cis.) treatment in control cells and cells with TRP53 down-regulation by either dCas9-
mediated transcriptional interference or RNAi. (H) qRT-PCR assessment of TRP53 and TRP53 target-gene levels after cisplatin treatment after interfering with
TRP53 expression levels. **P < 0.01 via Student’s t test. Data are represented as mean ± SEM.
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nearly all of the sgRNAs designed to target genomic DNA within
exon 1 (SI Appendix, Figs. S3 and S4). In contrast, targeting dCas9
upstream, or far downstream, of the TSS failed to significantly
interfere with TRP53 mRNA levels or confer resistance to cis-
platin. These assays all demonstrated a similar or bigger impact on
TRP53 expression levels and cellular function as the best TRP53
targeting shRNA found by tiling the TRP53 gene (39). Addition-
ally, we found that dCas9-mediated inactivation had profound
effects on TRP53’s capability to activate its downstream target
genes and in most cases, more so than the TRP53 shRNA (Fig. 1
G and H).
CRISPRi Is a Potent Tool for Modeling the Genetics of Cancer
Progression and Therapeutic Resistance in Vivo. Cas9 is part of the
adaptive immune system of Streptococcus pyogenes and is not
expressed in higher eukaryotes. Thus, if expressed in mammalian
systems, the protein might be recognized by a host immune
system and lead to adverse responses and graft rejection as re-
cently demonstrated in adenoviral delivery of Cas9 into liver
parenchyma (40). Furthermore, an application of dCas9 requires
the constant expression of both dCas9 and a sgRNA to enable
long-term genetic silencing. To explore the possibility of an in
vivo application of dCas9, we tail-vein injected pure populations
of Eμ-Myc p19Arf−/− cells expressing dCas9 and sgRNAs targeting
Trp53 along with multiple control constructs into syngeneic and
fully immunocompetent C57BL/6J mice (Fig. 2A). Mice were
euthanized upon disease onset and lymphoma cells were isolated
from lymph nodes. We then assessed TRP53 mRNA levels by
quantitative real-time PCR (qRT-PCR) and observed a strong
and consistent repression of TRP53 transcript levels in mice with
dCas9 targeted to Trp53 exon 1 (Fig. 2B). This level of TRP53
suppression exceeded the down-regulation seen in vitro and
suggested a selection of cells with a more potent inactivation of
TRP53 during disease progression. To determine whether this
extent of TRP53 loss was significant enough to impact the
speed of tumor development and response to chemotherapy, we
transplanted Eμ-Myc p19Arf−/− cells expressing dCas9 and either
a control sgRNA (Gal4) or either of two sgRNAs targeting Trp53
(T2, T3) into syngeneic C57BL/6J mice (25). Survival analysis
revealed that down-regulation of Trp53 by dCas9 is capable of
accelerating disease onset (Fig. 2C) and significantly reducing
overall survival (Fig. 2D). Furthermore, repression of Trp53
expression renders cells insensitive to cisplatin treatment in vivo,
with overall survival rates indistinguishable from matched con-
trol cohorts treated with vehicle alone (Fig. 2D and SI Appendix,
Fig. S5). Thus, dCas9-mediated transcriptional interference is
potent, long-lasting, and consistent enough to model the effect of
gene suppression on tumor progression. Most importantly, these
effects are preserved in vivo despite the presence of a fully
functional immune system.
Mgmt Transcriptional Activation via dCas9-VP64 Provokes Cellular
Resistance to Temozolomide in Vitro and in Vivo. Given the ability
to transcriptionally silence TRP53 both in vitro and in vivo using
dCas9, we next wanted to explore the feasibility of CRISPR-
mediated gene activation (CRISPRa) in vivo by using a dCas9
fusion to a fourfold repeat of the VP16 transcriptional activator
(VP64) (41) (Fig. 3 A and B and SI Appendix, Figs. S6 and S7).
We chose to target Mgmt (O6-methylguanine–DNA methyl-
transferase), a gene encoding a suicide enzyme known to detoxify
DNA lesions caused by the chemotherapeutic agent temozolo-
mide (TMZ) (42) (Fig. 3G). Epigenetic silencing of the Mgmt
gene renders cells more sensitive to TMZ, whereas high transcript
levels of MGMT are associated with a poor response to TMZ
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(43–45). We generated 10 unique sgRNAs targeting the genomic
region upstream of Mgmt’s TSS (Fig. 3C), transduced Bcr-Abl–
driven murine acute B-cell lymphoblastic leukemia cells (B-ALL)
with both dCas9-VP64 and single sgRNAs and analyzed MGMT
expression by both qRT-PCR and Western blot. Multiple sgRNAs
elicited a robust up-regulation of MGMT at both the mRNA and
protein levels (with 7 of 9 sgRNAs having more than twofold, 5 of 9
having more than fivefold, 3 of 9 having more than 10-fold, and 2 of
9 having more than 30-fold up-regulation of MGMTmRNA levels)
(Fig. 3 D–F and SI Appendix, Fig. S8). To determine whether the
observed gene activation confers protection to TMZ, we performed
in vitro drug dosing with TMZ for sgRNAs NT4, T4, and T6. As
expected, all three sgRNAs conferred resistance to TMZ (Fig. 3H).
Additionally, we compared the CRISPRa-mediated induction of
MGMT to an MGMT cDNA in terms of both expression and drug
resistance. Although both approaches yielded comparable protein
expression of MGMT, CRISPRa rendered cells significantly more
resistant to TMZ than the cDNA (SI Appendix, Fig. S9 A and B).
We next sought to determine whether CRISPRa could similarly
be used to model treatment response in vivo. We therefore
transplanted B-ALL cells infected with a combination of dCas9-
VP64 and sgRNAs either activatingMgmt transcription (NT4, T6)
or a nontargeting negative control (Gal4) into syngeneic and fully
immune-competent C57BL6/6J mice (Fig. 3I). Upon disease
manifestation, mice were either treated with TMZ or with vehicle.
Whereas the transcriptional activation of Mgmt did not have a
significant influence on mouse survival in the absence of treatment
(Fig. 3J), increased expression of MGMT lead to a substantial
resistance to TMZ treatment and to a significantly shorter sur-
vival of mice bearing tumors expressing sgRNAs NT4 and T6,
compared with Gal4-negative control tumors (Fig. 3K and SI
Appendix, Fig. S10). Importantly, the expression of dCas9-VP64
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with a nontargeting sgRNA did not have any significant influence
on survival if compared with the transplantation of nontransduced
cells, indicating that this system can be used in syngeneic immune-
competent in vivo experiments without fundamentally interfering
with disease kinetics per se (SI Appendix, Fig. S11). Thus, the
fusion of dCas9 to the transcriptional activator VP64 can be used
to strongly increase expression levels of MGMT and can rapidly
model the influence of genetic alterations on treatment relapse an
immune-competent model system in vivo.
RNAseq Demonstrates CRISPRi Has Negligible Off-Target Effects. It
has been shown via ChIP-Seq that dCas9 binds to a significant
number of off-target sites (46, 47). However, it is not known
whether these mere interactions have any functional relevance and
harbor the potency to cause off-target gene expression changes.
Thus, we wanted to determine how prone our dCas9 system is to
off-target effects. To address this question, we used our two best Trp53
sgRNAs, T2 and T3, in conjunction with tumor cells derived
from the well-established KrasLSL-G12D/+; p53fl/fl lung adenocar-
cinoma transgenic mouse model (48). In this model, after Cre-lox
recombination, the genomic binding sites for both sgRNAs are
maintained, whereas several downstream Trp53 coding exons are
deleted, abolishing TRP53’s ability to engage downstream effector
pathways (Fig. 4A). Thus, any changes in gene expression induced
by Trp53 sgRNAs can be considered off target. As a control, we
also included a negative control sgRNA, Gal4, which lacks any
predicted matches in the mouse genome. We first confirmed that
we could achieve dCas9-mediated knockdown in this cell line by
targeting and successfully suppressing Rev3l transcription (SI Ap-
pendix, Fig. S12). We next performed RNAseq and compared the
transcriptomes of cells either transduced with Trp53 sgRNAs T2/
T3 or with the control Gal4 sgRNA. To determine whether con-
sistent gene expression changes between the three groups might be
strong enough to cluster them next to one another, we conducted
unsupervised hierarchical clustering (Fig. 4B). We saw that instead
of clustering by sgRNA, clustering occurred by the biological
replicate, suggesting that the observed expression differences be-
tween sgRNAs were minimal. To better quantify potential off-
target transcript changes, we searched for significantly different
transcripts among the three sgRNAs across all replicates. A mere
three (Gal4 vs. Trp53 T2) and one (Gal4 vs. Trp53 T3) transcripts
were identified to be significantly differentially expressed [P < 0.01
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TRP53’s downstream effects. (B) Hierarchical clustering of KP cells stably transduced with dCas9 and either sgRNAs targeting Gal4 (nontargeting control),
Trp53 T2 or Trp53 T3. Text is colored by replicate. MA plots of genome-wide RNAseq data with significantly differentially regulated transcripts highlighted in
red (P < 0.01 after FDR adjustment) for Trp53 T2 vs. Gal4 (C), Trp53 T3 vs. Gal4 (D), and Trp53 T2 vs. Trp53 T3 (E).
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after false-discovery rate (FDR) adjustment] (Fig. 4 C and D). We
were not able to identify any differentially expressed transcripts
between T2 and T3 Trp53 sgRNAs (Fig. 4E). This result may in-
dicate that the lack of a perfectly matched binding site for the
Gal4 sgRNA permits a small level of binding promiscuity that is
not present for the Trp53 sgRNAs, for which perfect genomic
matches exist. Although the average number of reads aligning to
Trp53 were lower for both T2 and T3 in relation to Gal4, this
decrease was not significant (SI Appendix, Fig. S13).
The Position Relative to the TSS, Not the Functional Protein Domain
Associated with dCas9, Dictates the Direction of Transcriptional
Regulation. Given the ability of dCas9 to activate and repress
target gene expression, we were interested in determining whether
a single construct would be capable of both activating and deac-
tivating gene transcription. We therefore targeted either dCas9
alone or dCas9 linked to VP64 to different genomic regions
around the TSS of both Trp53 and Mgmt in ALL cells (Fig. 5A).
As shown before for Eμ-Myc p19Arf−/− cells, dCas9 targeted to a
genomic region downstream of Trp53’s TSS led to a potent de-
crease of transcript levels. Surprisingly, almost the same level of
TRP53 suppression could be achieved when dCas9-VP64 was
targeted to the same location (Fig. 5B). This finding suggests that
VP64 loses its activating capability if targeted downstream of the
TSS, and the associated dCas9 acts as a transcriptional roadblock
that interferes with transcriptional elongation. In contrast, tar-
geting dCas9-VP64 to a genomic region upstream of the TSS of
Mgmt led to a potent transcriptional activation, but targeting
dCas9 to this region caused a significant decrease of MGMT
mRNA levels, suggesting an interference with transcriptional ini-
tiation (Fig. 5B). To determine the generalizability of the ability of
dCas9-VP64 to repress transcription, we created 17 additional
sgRNAs targeting the genomic region downstream of the corre-
sponding TSSs of four more genes. For each gene, with five or
fewer sgRNAs, we were able to achieve substantial transcriptional
inhibition, ranging from 30 to 60% (Fig. 5C). Additionally, none
of the sgRNAs elicited mRNA up-regulation of their respective
target genes (SI Appendix, Fig. S14). This approach was also
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successful in a human glioblastoma cell line, T98G, in which each
of the sgRNAs tested elicited knockdown of MGMT (SI Appendix,
Fig. S15). To explore whether these transcriptional effects trans-
late into functional phenotypes, we treated ALL cells with either
cisplatin (Fig. 5D) or temozolomide (Fig. 5E). As predicted by the
changes in transcript levels, both dCas9 and dCas9-VP64 targeted
to exon 1 of Trp53 revealed resistance phenotypes to both cisplatin
and temozolomide treatment (Fig. 5 D and E). In contrast, only
the activation ofMgmt transcription by dCas9-VP64 led to cellular
resistance to temozolomide. To further demonstrate the robust-
ness of dCas9-VP64–mediated knockdown, we targeted Rev3l, the
catalytic subunit of the translesion polymerase Pol ζ. Whereas the
transcriptional repression of Rev3l is not expected to confer a
selective growth advantage to cells, lack of Rev3l sensitizes to
cisplatin treatment (49, 50). Indeed, all sgRNAs targeting Rev3l
significantly sensitized dCas9-VP64 ALL cells to cisplatin treat-
ment (SI Appendix, Fig. S16). We therefore concluded that a
dCas9 construct with a linked VP64 transcriptional activation
domain can be used for both transcriptional activation and re-
pression, depending on its relative position to the TSS. Thus,
CRISPRi and CRISPRa can be performed interchangeably using
the same dCas9 protein simply by altering the targeted DNA lo-
cation in respect to the corresponding TSS.
A Pooled in Vivo Gene Activation Screen Identifies Novel Mediators of
Bone Marrow Treatment Relapse in B-ALL. The construction of large
open-reading frame (ORF) libraries has made it possible to
screen for gain-of-function phenotypes (51); however, creation
of these libraries remains expensive and difficult. We were in-
terested in determining whether our Cas9-VP64–based system
was robust enough to perform pooled in vitro and in vivo pooled
screens. We therefore constructed a small sgRNA library tar-
geting 25 known or putative regulators of the DNA damage re-
sponse upstream of the TSS with a coverage of 5 sgRNAs per
gene and 50 additional nontargeting negative control sgRNAs
(SI Appendix, Fig. S17). The library was transduced into dCas9-
VP64–expressing B-ALL cells, and infected cells were purified
by flow cytometry-based sorting. SgRNA-expressing cells were in-
jected into syngeneic recipient mice or maintained in culture (Fig.
6A). Upon disease onset, mice and cells were treated in parallel
with TMZ or vehicle. After disease relapse, we isolated tumor cells
from the bone marrow of leukemic mice and extracted genomic
DNA from both the in vitro and the in vivo samples. Genomic
insertions were amplified by PCR, and the sgRNA representation
was deconvoluted via high-throughput sequencing. Sequencing re-
actions did not bias sgRNA quantification, and we were able to
detect most sgRNAs at more than 500 reads per sgRNA in both the
in vitro and in vivo samples (Fig. 6B and SI Appendix, Fig. S18). We
next sought to identify sgRNAs that impacted the cellular sensitivity
to TMZ by comparing the relative representation of each sgRNA in
the TMZ-treated group to its representation in the vehicle group
and generating a log(fold-change) value for each sgRNA (Dataset
S1). Using the negative control guide population as a null distri-
bution, we were able to assess significance levels of the observed
fold change effects either for single sgRNAs or on the gene level
by examining the effects of multiple sgRNA molecules targeting
the same gene. As expected, transcriptional activation of Mgmt
was identified to be the most potent resistance factor to TMZ
chemotherapy in vitro and in vivo (Fig. 6 C and D). Interestingly,
transcriptional activation of Checkpoint kinase 2 (Chek2), a major
signaling component of the DNA damage response network (52),
was identified as causing sensitivity to TMZ and slowing down
disease progression upon gene induction both in vitro and in vivo
(SI Appendix, Fig. S19). We therefore performed validation ex-
periments for two independent sgRNAs (Chek2-2 and Chek2-5) in
vivo. Closely matching our screen-based prediction, we found
CHEK2 up-regulation (SI Appendix, Fig. S20) extended survival in
the absence of treatment (Fig. 6E) and delayed disease relapse
after TMZ treatment (Fig. 6F) compared with control mice
without dCas9 targeted to the Chek2 genomic locus.
Discussion
This study describes an approach to dCas9-mediated gene level
perturbation that represents a robust, specific, and tractable tool
for modeling cancer progression and therapeutic relapse both in
vitro and in syngeneic immune-competent mouse models in vivo.
The guided genomic targeting of dCas9 along with the transcription
activating protein domain VP64 allows for the rapid and inexpen-
sive modeling of both gene activation and inactivation phenotypes
in one sgRNA per gene settings or in multiplexed pooled screens.
Thus, dCas9-mediated gene level changes represent an attractive
tool for both functional validation experiments and for unbiased
screening approaches. Additionally, because dCas9 does not gen-
erate different genetic entities in each individual cell, its use cir-
cumvents the requirement of the artifact-prone generation of single
cell clones, as often needed for Cas9-based studies.
Our in vivo gene activation screen identified Chek2, a serine
threonine kinase and candidate tumor suppressor gene, as delaying
both progression and therapeutic relapse of B-ALL in vivo upon
transcriptional activation. Notably, certain inactivating or protein-
destabilizing mutations of the human CHEK2 gene have been im-
plicated in the development of multiple cancers (especially breast
and prostate) (53). Furthermore, CHEK2 expression is frequently
reduced in cancer cell lines (54). Oncogenic stress or DNA lesions
can cause an activation of CHEK2, which is then capable of driving
cells into apoptosis mediated by TP53 (55). High levels of CHEK2
in tumor cell lines are frequently associated with the inactivation of
p53 (54). Here, we demonstrate that the transcriptional activation
of Chek2 in the presence of a wild-type TRP53 is capable of slowing
down tumor progression and sensitizing to chemotherapy. It re-
mains to be explored whether this phenotype is exclusive to tumor
cells without inactivation of TRP53.
Interestingly, we observed some discordance in the amounts of
mRNA and protein up-regulation for MGMT following CRISPRa.
It is unclear whether this discordance represents a universal effect
connected to the activation of the endogenous transcription ma-
chinery as opposed to overexpression of a codon-optimized and
virally introduced gene coding sequence.
One key feature of dCas9-mediated transcriptional activation is the
ability to rapidly and cost-effectively generate large sgRNA libraries.
This finding stands in contrast to the construction of cDNA/ORF
libraries, which, because of extreme heterogeneity in gene length, are
protracted and expensive undertakings. Here, we demonstrate, for
the first time to our knowledge, that gene activation screens based on
CRISPRa, detecting both sgRNA enrichment and depletion, are
feasible in vivo and can obviate many of the technical bottlenecks of
gene overexpression screens in mouse models of cancer.
The construction of a Cre-dependent Rosa26 Cas9 knock-in
mouse has recently helped to decrease delivery vector sizes and to
make in vivo genome editing of nontumor cells possible, even if
they are located in anatomical loci that are hard to access (56). The
combination of this approach along with dCas9-based in vivo
functionality should allow for the study of gene activation pheno-
types in diverse and physiologically relevant contexts; this includes
pooled screens for genetic factors of organ development, as has
been demonstrated in a genome-wide fashion using RNAi (57).
Importantly, the scarcity of transcriptional alterations in our
dCas9 control experiments suggests that CRISPRa screening
may not be encumbered by significant off-target effects. This
finding is perhaps unexpected given Cas9’s promiscuous binding
to many genomic loci in published Chip-Seq data (46, 47) and
suggests that the vast majority of these off-target genome–Cas9
interactions are functionally irrelevant. Thus, data from pooled
dCas9 screens may be much easier to deconvolute than expected,
and that the rate of false-positive screening hits may be quite low
relative to other screening approaches.
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Materials and Methods
Vector Generation and sgRNA Library Cloning. dCas9 fused to two C-terminal
SV40 NLSs was derived from pHR-SFFV-dCas9-BFP (32) (see SI Appendix, SI
Materials and Methods for cloning strategies). sgRNAs were cloned into U6-
sgRNA-CMV-tdTomato as described (30) (targeted genomic sequences can
be found in SI Appendix, Table S1). Construction of the screen library is
described in SI Appendix, Fig. S17.
Cell Culture. Eμ-Myc p19Arf−/− mouse B-cell lymphomas were cultured in B-cell
medium (45% DMEM/45% IMDM/10% FBS, supplemented with 2 mM L-gluta-
mine and 5 μM β-mercaptoethanol). Bcr-Abl–driven mouse B-ALL leukemia cells
(58) were cultured in RPMI supplemented with 10% FBS, 4 mM L-glutamine, and
5 μM β-mercaptoethanol. Lung adenocarcinoma cells (KP cells) had been derived
from KrasLSL-G12D p53fl mice after Cre-mediated recombination and tumor onset
(48) and were cultured in DMEM complete medium (90% DMEM/10% FBS).
T98G cells were purchased from ATCC (CRL-1690) and cultured in DMEM com-
plete medium (90%DMEM/10% FBS). See SI Appendix, SI Materials andMethods
for virus production, drug treatment, and flow cytometry.
RNA Interference. The shRNA targeting p53 was expressed in a mir30 context
as described (59) targeting the following mRNA sequence: CCACTACAAGTA-
CATGTGTAA.
Total RNA Purification, cDNA Synthesis, and qRT-PCR. Total RNAwas isolated by
using the NucleoSpin RNA kit (Machery-Nagel). To quantify gene expression
levels, equal amounts of cDNA were synthesized by using the PrimeScript RT
reagent Kit with gDNA Eraser (Takara), mixed with the Fast SYBR Green
Mastermix (Applied Biosystems), and gene expression was analyzed with a
StepOnePlus Real-Time PCR System (Applied Biosystems). Primer sequences are
listed in SI Appendix, Table S2. The number of cycles required to cross a
fluorescence threshold (CT value) was noted for each transcript and normal-
ized to GAPDH.
RNAseq. See SI Appendix, SI Materials and Methods for RNA extraction, li-
brary preparation, sequencing, and analysis. In brief, DESeq was used to
determine FDR-adjusted P values for transcripts that were significantly
differentially expressed. Transcripts that did not pass the expression threshold
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of >0.2 fragments per kilobase of fragment per million mapped reads and a
variability threshold of >0.2 SD across replicates were eliminated from analysis.
Western Blot. Protein extracts, separatedby SDS/PAGEand transferredontoPVDF
membranes, were probed with antibodies against stated proteins. See SI Ap-
pendix, SI Materials and Methods for antibody list and visualization method.
Transplantation of Eμ-Myc p19Arf−/− or B-ALL Cells into Immune-Competent
Syngeneic Mice and in Vivo Drug Treatment. Six-week-old female C57BL/6J
mice were purchased from the Jackson Laboratory (stock no. 000664); 2 × 106
cells per mouse were transplanted by tail-vein injection in 200 μL of PBS. All
mouse experiments were approved by Massachusetts Institute of Technol-
ogy’s Committee on Animal Care prior to execution. See SI Appendix, SI
Materials and Methods for drug treatment.
In Vitro and in Vivo sgRNA Screen. Briefly, B-ALL cells were first infected with
both dCas9-VP64 and a custom sgRNA library [targeting the genomic DNA
region upstream of the TSS of genes previously implicated into the response
to DNA damage (125 sgRNAs targeting genomic DNA regions and 50
negative control sgRNAs)]. See Fig. 6A and SI Appendix, SI Materials and
Methods for screening strategy and experimental details.
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